Rain Therapeutics raises $125m for IPO
Rain Therapeutics, a developer of precision oncology therapeutics, has raised about $125 million for its IPO after pricing its over 7.3 million shares at $17 per share.
Nearly there!
A verification email is on its way to you. Please check your spam or junk folder just in case.
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: subscriptions@pei.group .-
Sign in or Register
-
Issues with signing in? Click here
Don't have an account? Register now
-
